Clearside Biomedical Stock Price, News & Analysis (NASDAQ:CLSD)

$7.26 0.09 (1.26 %)
(As of 11/24/2017 02:29 AM ET)
Previous Close$7.17
Today's Range$7.01 - $7.53
52-Week Range$5.44 - $22.97
Volume53,846 shs
Average Volume153,260 shs
Market Capitalization$181.71 million
P/E RatioN/A
Dividend YieldN/A
Beta-11.76

About Clearside Biomedical (NASDAQ:CLSD)

Clearside Biomedical logoClearside Biomedical, Inc. is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company's product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment. With its microinjector, drugs are injected into and spread within and through the suprachoroidal space, (SCS), which is the space located between the choroid and the outer protective layer of the eye known as the sclera. With the suprachoroidal injection, its product candidates are more directly administered to the retina and choroid as compared to other ocular drug administration techniques, such as injections of drug into the vitreous, a jelly-like substance that occupies the central portion of the eye.

Receive CLSD News and Ratings via Email

Sign-up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CLSD
CUSIPN/A
Phone678-270-3631

Debt

Debt-to-Equity Ratio0.15%
Current Ratio4.57%
Quick Ratio4.57%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$520,000.00
Price / Sales353.79
Cash FlowN/A
Price / CashN/A
Book Value$1.46 per share
Price / Book4.97

Profitability

Trailing EPS($2.12)
Net Income$-25,880,000.00
Net Margins-17,684.07%
Return on Equity-90.72%
Return on Assets-71.95%

Miscellaneous

Employees24
Outstanding Shares25,340,000

Frequently Asked Questions for Clearside Biomedical (NASDAQ:CLSD)

What is Clearside Biomedical's stock symbol?

Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."

How were Clearside Biomedical's earnings last quarter?

Clearside Biomedical, Inc. (NASDAQ:CLSD) released its quarterly earnings results on Wednesday, November, 8th. The company reported ($0.72) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.55) by $0.17. The business had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.01 million. Clearside Biomedical had a negative net margin of 17,684.07% and a negative return on equity of 90.72%. View Clearside Biomedical's Earnings History.

Where is Clearside Biomedical's stock going? Where will Clearside Biomedical's stock price be in 2017?

5 brokers have issued 12-month price objectives for Clearside Biomedical's shares. Their forecasts range from $15.00 to $27.00. On average, they expect Clearside Biomedical's stock price to reach $20.00 in the next year. View Analyst Ratings for Clearside Biomedical.

What are Wall Street analysts saying about Clearside Biomedical stock?

Here are some recent quotes from research analysts about Clearside Biomedical stock:

  • 1. According to Zacks Investment Research, "Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space(TM) microinjector. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia. " (11/13/2017)
  • 2. Needham & Company LLC analysts commented, "CLSD reported 4Q16 financials and updated its ongoing development programs. The most advanced program evaluating suprachoroidal CLSTA as a treatment for macular edema associated with uveitis continues to enroll patients and is on track to report ph 3 results from the PEACHTREE trial in early-2018. Last month, CLSD initiated its second pivotal ph 3 program with the SAPPHIRE study designed to evaluate the concomitant use of suprachoroidal CLS-TA with Eylea (aflibercept) for treating macular edema associated with RVO. Top-line RVO results are expected in 2H18. Recently, CLSD halted its wet-AMD program to focus on the DME progrma and the exploratory Ph 1/2 HULK trial. If positive, a ph 2 DME study is expected to initiate in mid-2017. We maintain our Buy rating and adjust our $PT to $18 (from $24)." (3/14/2017)
  • 3. Wedbush analysts commented, "We consider CLSD to be a buying opportunity due to an attractive valuation in front of multiple clinical and business catalysts anticipated by the end of 2017. With around $90 million in pro forma cash, we believe Clearside is well capitalized to cover multiple catalysts in 2017 and 2018 from pipeline progress with multiple clinical programs ongoing (ME-NIU, ME-RVO, DME) and an additional program for wet AMD." (2/21/2017)

Who are some of Clearside Biomedical's key competitors?

Who are Clearside Biomedical's key executives?

Clearside Biomedical's management team includes the folowing people:

  • Christy L. Shaffer Ph.D., Chairman of the Board (Age 59)
  • Daniel H. White, President, Chief Executive Officer, Director (Age 50)
  • Charles A. Deignan, Chief Financial Officer (Age 52)
  • Glenn Noronha Ph.D., Chief Scientific Officer (Age 52)
  • Rafael V. Andino, Vice President - Engineering & Manufacturing
  • George Lasezkay J.D., Director (Age 65)
  • Gerald D. Cagle Ph.D., Independent Director (Age 72)
  • Richard J. Croarkin, Independent Director (Age 62)
  • William D. Humphries, Independent Director (Age 50)
  • Clay B. Thorp, Independent Director (Age 48)

When did Clearside Biomedical IPO?

(CLSD) raised $50 million in an IPO on Thursday, June 2nd 2016. The company issued 7,200,000 shares at $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

Who owns Clearside Biomedical stock?

Clearside Biomedical's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include GSA Capital Partners LLP (0.25%), Granite Investment Partners LLC (0.24%) and Wedbush Securities Inc. (0.12%). Company insiders that own Clearside Biomedical stock include Charles A Deignan, Christy L Shaffer, Clay Thorp, Daniel H White, Gerald D Cagle, Venture Advisors Iii Hatteras and Venture Advisors Iv S Hatteras. View Institutional Ownership Trends for Clearside Biomedical.

Who sold Clearside Biomedical stock? Who is selling Clearside Biomedical stock?

Clearside Biomedical's stock was sold by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC. Company insiders that have sold Clearside Biomedical company stock in the last year include Clay Thorp, Daniel H White and Venture Advisors Iii Hatteras. View Insider Buying and Selling for Clearside Biomedical.

Who bought Clearside Biomedical stock? Who is buying Clearside Biomedical stock?

Clearside Biomedical's stock was bought by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP and Wedbush Securities Inc.. Company insiders that have bought Clearside Biomedical stock in the last two years include Charles A Deignan, Christy L Shaffer, Gerald D Cagle and Venture Advisors Iv S Hatteras. View Insider Buying and Selling for Clearside Biomedical.

How do I buy Clearside Biomedical stock?

Shares of Clearside Biomedical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Clearside Biomedical's stock price today?

One share of Clearside Biomedical stock can currently be purchased for approximately $7.26.

How big of a company is Clearside Biomedical?

Clearside Biomedical has a market capitalization of $181.71 million and generates $520,000.00 in revenue each year. The company earns $-25,880,000.00 in net income (profit) each year or ($2.12) on an earnings per share basis. Clearside Biomedical employs 24 workers across the globe.

How can I contact Clearside Biomedical?

Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The company can be reached via phone at 678-270-3631 or via email at [email protected]


MarketBeat Community Rating for Clearside Biomedical (CLSD)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  116 (Vote Outperform)
Underperform Votes:  87 (Vote Underperform)
Total Votes:  203
MarketBeat's community ratings are surveys of what our community members think about Clearside Biomedical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Clearside Biomedical (NASDAQ:CLSD)

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.632.503.00
Ratings Breakdown: 2 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $19.00$19.00$19.00$20.50
Price Target Upside: 160.27% upside153.00% upside167.61% upside171.88% upside

Consensus Price Target History for Clearside Biomedical (NASDAQ:CLSD)

Price Target History for Clearside Biomedical (NASDAQ:CLSD)

Analysts' Ratings History for Clearside Biomedical (NASDAQ:CLSD)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/25/2017Cowen IncReiterated RatingBuyN/AView Rating Details
5/25/2017JMP SecuritiesInitiated CoverageMkt Outperform -> Outperform$21.00LowView Rating Details
4/20/2017WedbushReiterated RatingOutperform$27.00LowView Rating Details
3/14/2017Needham & Company LLCLower Price TargetBuy$18.00HighView Rating Details
2/24/2017J P Morgan Chase & CoInitiated CoverageOverweight -> Overweight$19.00N/AView Rating Details
10/24/2016Stifel NicolausBoost Price TargetBuy$13.00 -> $23.00N/AView Rating Details
(Data available from 11/25/2015 forward)

Earnings

Earnings History and Estimates Chart for Clearside Biomedical (NASDAQ:CLSD)

Earnings by Quarter for Clearside Biomedical (NASDAQ:CLSD)

Earnings History by Quarter for Clearside Biomedical (NASDAQ CLSD)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 2017($0.55)($0.72)$0.01 million$0.16 millionViewN/AView Earnings Details
8/9/20176/30/2017($0.41)($0.54)$0.13 millionViewListenView Earnings Details
5/10/20173/31/2017($0.44)($0.41)$0.01 millionViewN/AView Earnings Details
3/14/2017Q4 2016($0.33)($0.45)$0.01 million$0.01 millionViewN/AView Earnings Details
11/9/20169/30/2016($0.45)($0.28)$0.01 million$0.01 millionViewListenView Earnings Details
8/11/2016Q2($0.32)($0.62)$0.01 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Clearside Biomedical (NASDAQ:CLSD)
2017 EPS Consensus Estimate: ($1.63)
2018 EPS Consensus Estimate: ($2.60)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.38)($0.38)($0.38)
Q2 20171($0.41)($0.41)($0.41)
Q3 20171($0.42)($0.42)($0.42)
Q4 20171($0.42)($0.42)($0.42)
Q1 20181($0.61)($0.61)($0.61)
Q2 20181($0.63)($0.63)($0.63)
Q3 20181($0.66)($0.66)($0.66)
Q4 20181($0.70)($0.70)($0.70)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Clearside Biomedical (NASDAQ:CLSD)

No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Clearside Biomedical (NASDAQ CLSD)

Insider Ownership Percentage: 20.90%
Institutional Ownership Percentage: 52.40%
Insider Trades by Quarter for Clearside Biomedical (NASDAQ:CLSD)
Institutional Ownership by Quarter for Clearside Biomedical (NASDAQ:CLSD)

Insider Trades by Quarter for Clearside Biomedical (NASDAQ CLSD)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/16/2017Clay ThorpDirectorSell35,000$7.00$245,000.00View SEC Filing  
11/14/2017Clay ThorpDirectorSell15,000$7.02$105,300.00View SEC Filing  
10/19/2017Daniel H WhiteInsiderSell8,000$7.82$62,560.00View SEC Filing  
10/5/2017Clay ThorpDirectorSell35,000$8.57$299,950.00View SEC Filing  
9/15/2017Clay ThorpDirectorSell24,500$7.52$184,240.00View SEC Filing  
9/14/2017Clay ThorpDirectorSell6,000$7.52$45,120.00View SEC Filing  
9/13/2017Clay ThorpDirectorSell8,500$7.49$63,665.00View SEC Filing  
9/8/2017Daniel H WhiteInsiderSell16,000$7.57$121,120.00View SEC Filing  
8/15/2017Christy L ShafferDirectorBuy1,100$7.00$7,700.00View SEC Filing  
8/14/2017Charles A DeignanCFOBuy1,000$7.07$7,070.00View SEC Filing  
8/11/2017Gerald D CagleDirectorBuy5,000$7.08$35,400.00View SEC Filing  
8/9/2017Clay ThorpDirectorSell24,500$7.57$185,465.00View SEC Filing  
8/8/2017Clay ThorpDirectorSell5,000$7.98$39,900.00View SEC Filing  
8/7/2017Clay ThorpDirectorSell4,500$8.02$36,090.00View SEC Filing  
7/20/2017Daniel H WhiteInsiderSell8,000$9.75$78,000.00View SEC Filing  
7/19/2017Daniel H WhiteCEOSell3,600$9.79$35,244.00View SEC Filing  
6/14/2017Daniel H WhiteInsiderSell8,000$7.89$63,120.00View SEC Filing  
6/13/2017Daniel H WhiteCEOSell3,600$7.78$28,008.00View SEC Filing  
5/22/2017Christy L ShafferDirectorBuy1,100$8.00$8,800.00View SEC Filing  
5/19/2017Clay ThorpDirectorSell24,000$8.36$200,640.00View SEC Filing  
5/18/2017Daniel H WhiteInsiderSell8,000$8.41$67,280.00View SEC Filing  
5/17/2017Clay ThorpDirectorSell44,485$8.63$383,905.55View SEC Filing  
5/16/2017Clay ThorpDirectorSell9,544$8.61$82,173.84View SEC Filing  
5/15/2017Clay ThorpDirectorSell15,941$8.94$142,512.54View SEC Filing  
4/19/2017Clay ThorpDirectorSell68,485$7.46$510,898.10View SEC Filing  
4/18/2017Clay ThorpDirectorSell44,455$7.48$332,523.40View SEC Filing  
4/17/2017Clay ThorpDirectorSell22,000$7.43$163,460.00View SEC Filing  
4/4/2017Daniel H WhiteInsiderSell8,000$7.55$60,400.00View SEC Filing  
4/3/2017Daniel H WhiteCEOSell3,600$7.56$27,216.00View SEC Filing  
3/20/2017Christy L ShafferDirectorBuy2,200$6.90$15,180.00View SEC Filing  
3/16/2017Clay ThorpDirectorSell68,485$6.56$449,261.60View SEC Filing  
2/22/2017Clay ThorpDirectorSell27,000$7.55$203,850.00View SEC Filing  
2/17/2017Clay ThorpDirectorSell41,485$7.60$315,286.00View SEC Filing  
1/20/2017Clay ThorpDirectorSell68,485$8.53$584,177.05View SEC Filing  
1/19/2017Venture Advisors Iii HatterasInsiderSell25,301$8.63$218,347.63View SEC Filing  
6/7/2016Clay ThorpDirectorSell138$7.00$966.00View SEC Filing  
6/7/2016Venture Advisors Iv S HatterasMajor ShareholderBuy414,286$7.00$2,900,002.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Clearside Biomedical (NASDAQ CLSD)

Source:
DateHeadline
Clearside Biomedical, Inc. :CLSD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 21, 2017Clearside Biomedical, Inc. :CLSD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 21, 2017
finance.yahoo.com - November 21 at 5:26 PM
Analyzing Clearside Biomedical (CLSD) and Adaptimmune Therapeutics PLC (ADAP)Analyzing Clearside Biomedical (CLSD) and Adaptimmune Therapeutics PLC (ADAP)
www.americanbankingnews.com - November 20 at 1:30 AM
Clearside Biomedical, Inc. (CLSD) Director Clay Thorp Sells 15,000 SharesClearside Biomedical, Inc. (CLSD) Director Clay Thorp Sells 15,000 Shares
www.americanbankingnews.com - November 16 at 8:57 PM
Insider Selling: Clearside Biomedical, Inc. (CLSD) Director Sells 35,000 Shares of StockInsider Selling: Clearside Biomedical, Inc. (CLSD) Director Sells 35,000 Shares of Stock
www.americanbankingnews.com - November 16 at 8:37 PM
Clearside Biomedical’s Phase 1/2 Open Label Clinical Trial of CLS-TA With and Without Eylea in Diabetic Macular Edema Presented at the American Academy of Ophthalmology 2017 Annual MeetingClearside Biomedical’s Phase 1/2 Open Label Clinical Trial of CLS-TA With and Without Eylea in Diabetic Macular Edema Presented at the American Academy of Ophthalmology 2017 Annual Meeting
finance.yahoo.com - November 13 at 10:37 PM
Clearside Biomedical, Inc. (CLSD) Downgraded to Sell at Zacks Investment ResearchClearside Biomedical, Inc. (CLSD) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - November 13 at 8:30 PM
Clearside Biomedical, Inc. to Participate in Stifel 2017 Healthcare ConferenceClearside Biomedical, Inc. to Participate in Stifel 2017 Healthcare Conference
feeds.benzinga.com - November 13 at 5:49 PM
Clearside Biomedical, Inc. (CLSD) Receives Average Rating of "Buy" from BrokeragesClearside Biomedical, Inc. (CLSD) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - November 12 at 4:04 AM
Clearside Biomedical (CLSD) CEO Daniel White on Q3 2017 Results - Earnings Call TranscriptClearside Biomedical (CLSD) CEO Daniel White on Q3 2017 Results - Earnings Call Transcript
www.msn.com - November 10 at 9:49 AM
Clearside Biomedical, Inc. (CLSD) Announces  Earnings Results, Misses Expectations By $0.17 EPSClearside Biomedical, Inc. (CLSD) Announces Earnings Results, Misses Expectations By $0.17 EPS
www.americanbankingnews.com - November 9 at 5:44 PM
Clearside Biomedical, Inc. to Host Earnings CallClearside Biomedical, Inc. to Host Earnings Call
finance.yahoo.com - November 8 at 9:17 PM
Clearside Biomedical, Inc. Announces Third Quarter 2017 Financial Results and Provides Corporate UpdateClearside Biomedical, Inc. Announces Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - November 8 at 9:17 PM
Clearside Biomedical (CLSD) & Its Competitors Financial ComparisonClearside Biomedical (CLSD) & Its Competitors Financial Comparison
www.americanbankingnews.com - November 2 at 5:30 AM
Clearside Biomedical, Inc. to Report Third Quarter 2017 Financial Results on November 8, 2017 – Conference Call to FollowClearside Biomedical, Inc. to Report Third Quarter 2017 Financial Results on November 8, 2017 – Conference Call to Follow
finance.yahoo.com - November 1 at 6:05 PM
Clearside Biomedical, Inc. (CLSD) to Release Quarterly Earnings on TuesdayClearside Biomedical, Inc. (CLSD) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:08 AM
Clearside Biomedical, Inc. (CLSD) Rating Increased to Hold at Zacks Investment ResearchClearside Biomedical, Inc. (CLSD) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - October 25 at 7:52 PM
CLSD Progressing With TYBEE, SNY In Legal Spat With MYL, TBPH On WatchCLSD Progressing With TYBEE, SNY In Legal Spat With MYL, TBPH On Watch
www.rttnews.com - October 25 at 5:41 AM
Clearside Biomedical (CLSD) Reports Completion of Patient Enrollment in Phase 2 Clinical Trial of CLS-TAClearside Biomedical (CLSD) Reports Completion of Patient Enrollment in Phase 2 Clinical Trial of CLS-TA
www.streetinsider.com - October 25 at 5:41 AM
Clearside Biomedical Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CLS-TA Used Together with Eylea in Patients with Diabetic Macular EdemaClearside Biomedical Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CLS-TA Used Together with Eylea in Patients with Diabetic Macular Edema
finance.yahoo.com - October 24 at 7:40 PM
Clearside Biomedical, Inc. (CLSD) Insider Daniel H. White Sells 8,000 SharesClearside Biomedical, Inc. (CLSD) Insider Daniel H. White Sells 8,000 Shares
www.americanbankingnews.com - October 23 at 10:28 AM
Clearside Biomedical (CLSD) and Akari Therapeutics PLC (AKTX) Financial AnalysisClearside Biomedical (CLSD) and Akari Therapeutics PLC (AKTX) Financial Analysis
www.americanbankingnews.com - October 21 at 12:26 AM
Clearside Biomedical, Inc. (CLSD) Receives Average Rating of "Buy" from AnalystsClearside Biomedical, Inc. (CLSD) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - October 18 at 6:54 AM
ETFs with exposure to Clearside Biomedical, Inc. : October 11, 2017ETFs with exposure to Clearside Biomedical, Inc. : October 11, 2017
finance.yahoo.com - October 11 at 6:46 PM
Clearside Biomedical, Inc. (CLSD) Director Clay Thorp Sells 35,000 SharesClearside Biomedical, Inc. (CLSD) Director Clay Thorp Sells 35,000 Shares
www.americanbankingnews.com - October 5 at 10:28 PM
ETFs with exposure to Clearside Biomedical, Inc. : September 28, 2017ETFs with exposure to Clearside Biomedical, Inc. : September 28, 2017
finance.yahoo.com - October 2 at 5:36 PM
PRO Weekly Digest: All About Due Diligence With Cliffside ResearchPRO Weekly Digest: All About Due Diligence With Cliffside Research
seekingalpha.com - September 24 at 4:41 PM
Clearside Biomedical, Inc. (CLSD) Given Consensus Recommendation of "Buy" by AnalystsClearside Biomedical, Inc. (CLSD) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - September 23 at 4:38 AM
Insider Selling: Clearside Biomedical, Inc. (CLSD) Director Sells 8,500 Shares of StockInsider Selling: Clearside Biomedical, Inc. (CLSD) Director Sells 8,500 Shares of Stock
www.americanbankingnews.com - September 15 at 8:28 PM
Clay Thorp Sells 6,000 Shares of Clearside Biomedical, Inc. (CLSD) StockClay Thorp Sells 6,000 Shares of Clearside Biomedical, Inc. (CLSD) Stock
www.americanbankingnews.com - September 15 at 8:28 PM
Clearside Biomedical, Inc. (CLSD) Director Clay Thorp Sells 24,500 SharesClearside Biomedical, Inc. (CLSD) Director Clay Thorp Sells 24,500 Shares
www.americanbankingnews.com - September 15 at 8:04 PM
Insider Selling: Clearside Biomedical, Inc. (CLSD) Insider Sells 16,000 Shares of StockInsider Selling: Clearside Biomedical, Inc. (CLSD) Insider Sells 16,000 Shares of Stock
www.americanbankingnews.com - September 11 at 7:50 PM
ETFs with exposure to Clearside Biomedical, Inc. : August 31, 2017ETFs with exposure to Clearside Biomedical, Inc. : August 31, 2017
finance.yahoo.com - August 31 at 10:13 PM
Clearside Biomedical, Inc. (CLSD) Given Consensus Recommendation of "Buy" by BrokeragesClearside Biomedical, Inc. (CLSD) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - August 29 at 4:32 AM
Clearside Biomedical, Inc. (CLSD) to Post Q1 2018 Earnings of ($0.61) Per Share, Wedbush ForecastsClearside Biomedical, Inc. (CLSD) to Post Q1 2018 Earnings of ($0.61) Per Share, Wedbush Forecasts
www.americanbankingnews.com - August 28 at 4:46 AM
Clearside Biomedical, Inc. :CLSD-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017Clearside Biomedical, Inc. :CLSD-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 5:23 PM
Clearside Biomedical, Inc. (CLSD) Rating Lowered to D at TheStreetClearside Biomedical, Inc. (CLSD) Rating Lowered to D at TheStreet
www.americanbankingnews.com - August 16 at 12:32 AM
Insider Buying: Clearside Biomedical, Inc. (CLSD) Director Acquires 5,000 Shares of StockInsider Buying: Clearside Biomedical, Inc. (CLSD) Director Acquires 5,000 Shares of Stock
www.americanbankingnews.com - August 15 at 8:26 PM
Clearside Biomedical, Inc. (CLSD) Posts Quarterly  Earnings Results, Misses Estimates By $0.13 EPSClearside Biomedical, Inc. (CLSD) Posts Quarterly Earnings Results, Misses Estimates By $0.13 EPS
www.americanbankingnews.com - August 10 at 8:02 PM
Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Sells $36,090.00 in StockClearside Biomedical, Inc. (NASDAQ:CLSD) Director Sells $36,090.00 in Stock
www.americanbankingnews.com - August 9 at 9:32 PM
Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Sells $39,900.00 in StockClearside Biomedical, Inc. (NASDAQ:CLSD) Director Sells $39,900.00 in Stock
www.americanbankingnews.com - August 9 at 9:32 PM
Clearside Biomedical, Inc. (CLSD) Director Sells $185,465.00 in StockClearside Biomedical, Inc. (CLSD) Director Sells $185,465.00 in Stock
www.americanbankingnews.com - August 9 at 9:04 PM
Clearside Biomedical, Inc. Announces Second Quarter 2017 Financial Results and Provides Corporate UpdateClearside Biomedical, Inc. Announces Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 9 at 5:29 PM
Clearside Biomedical, Inc. Announces Second Quarter 2017 Financial Results and Provides Corporate UpdateClearside Biomedical, Inc. Announces Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 9 at 5:29 PM
Clearside Biomedical, Inc. Announces Changes to its Board of DirectorsClearside Biomedical, Inc. Announces Changes to its Board of Directors
finance.yahoo.com - August 8 at 5:03 PM
Clearside Biomedical, Inc. Announces Participation in Upcoming EventsClearside Biomedical, Inc. Announces Participation in Upcoming Events
finance.yahoo.com - August 8 at 5:03 PM
Clearside Biomedical (CLSD) Reports Completion of Patient Enrollment in Pivotal Phase 3 PEACHTREE Clinical Trial of CLS-TAClearside Biomedical (CLSD) Reports Completion of Patient Enrollment in Pivotal Phase 3 PEACHTREE Clinical Trial of CLS-TA
www.streetinsider.com - August 7 at 10:45 PM
Cowen and Company Reaffirms "Buy" Rating for Clearside Biomedical, Inc. (CLSD)Cowen and Company Reaffirms "Buy" Rating for Clearside Biomedical, Inc. (CLSD)
www.americanbankingnews.com - August 7 at 6:20 PM
Clearside Biomedical Announces Completion of Patient Enrollment in Pivotal Phase 3 PEACHTREE Clinical Trial of CLS-TA for Suprachoroidal Administration in Patients with Macular Edema Associated with Non-Infectious UveitisClearside Biomedical Announces Completion of Patient Enrollment in Pivotal Phase 3 PEACHTREE Clinical Trial of CLS-TA for Suprachoroidal Administration in Patients with Macular Edema Associated with Non-Infectious Uveitis
finance.yahoo.com - August 7 at 5:43 PM
Clearside Biomedical Announces Completion of Patient Enrollment in Pivotal Phase 3 PEACHTREE Clinical Trial of CLS-TA for Suprachoroidal Administration in Patients with Macular Edema Associated with Non-Infectious UveitisClearside Biomedical Announces Completion of Patient Enrollment in Pivotal Phase 3 PEACHTREE Clinical Trial of CLS-TA for Suprachoroidal Administration in Patients with Macular Edema Associated with Non-Infectious Uveitis
finance.yahoo.com - August 7 at 5:43 PM
Clearside Biomedical, Inc. to Report Second Quarter 2017 Financial Results on August 9, 2017 – Conference Call to FollowClearside Biomedical, Inc. to Report Second Quarter 2017 Financial Results on August 9, 2017 – Conference Call to Follow
finance.yahoo.com - August 2 at 6:03 PM

Social Media

Financials

Chart

Clearside Biomedical (NASDAQ CLSD) Chart for Saturday, November, 25, 2017
Loading chart…

This page was last updated on 11/25/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.